Tracers / [153Sm]Sm-BPAMD

[153Sm]Sm-BPAMD

Also written as Sm-153-BPAMD

Radionuclide: Sm-153 t½ 2776.8 min
Modality: Therapy
Production route: —
Stage: preclinical
Syntheses indexed: 0

Bone metastases and bone lesions Dosimetry and biodistribution studies

What it is

Compound class: 153Sm-labelled bisphosphonate bone-seeking agent
Target / mechanism: bone surface (hydroxyapatite mineral binding via bisphosphonate) PMID 26095757
Clinical application: Bone pain palliation therapy PMID 26095757
Theranostic pair: <a href="/tracers/ga68-bpamd/">ga68-bpamd</a>

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

No synthesis has been parsed for this agent yet.

Need this precursor?We can point you to suppliers for [153Sm]Sm-BPAMD, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 1 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Diagnostic pair signal at discovery: YES - Ga-68.